Piramal Pharma Limited has informed the Exchange about Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at Turbhe
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Piramal Pharma Limited announced that the US FDA has issued an Establishment Inspection Report (EIR) with VAI (Voluntary Action Indicated) classification for its Turbhe manufacturing facility. This follows the General GMP inspection conducted from 11th to 17th February 2025. The VAI classification means the facility was found to be in acceptable compliance with GMP regulations with no significant regulatory action required. This marks the successful closure of the inspection process that began earlier this year.
Positive for shareholders — VAI classification indicates satisfactory regulatory compliance, reducing compliance risk and supporting uninterrupted operations and exports from the Turbhe facility. This removes regulatory overhang and is likely to be viewed favorably by the market.